A second October suspension

TSP Advanced Technologies PLC (LSE:TSP) has had trading in its shares suspended on the Aquis Stock Exchange after failing to publish its audited annual accounts on time. The question this article examines is why the spinal technology developer finds itself suspended for the second October in a row, and what its most recent financial disclosures say about its position. The answer draws on the suspension notice and the company's last published half-year report.

The company

TSP Advanced Technologies, which changed its name from TruSpine Technologies in November 2025, is quoted on the Access segment of the Aquis Growth Market under the code TSP. It develops products for spinal fusion applications and has not yet generated Revenue from operations. Geoff Miller chairs the board, and Cairn Financial Advisers acts as its Aquis corporate adviser. The company's financial year ended on 29 March 2026.

The 1 October announcement

On 1 October 2026, the company announced a delay to the publication of its audited accounts for the year ended 29 March 2026. As a result, it said "a temporary suspension of trading in the Company's shares will take effect from 08:00 today (1 October 2026)," under Rule 5.1 of the Aquis Growth Market Access Rulebook. The announcement did not give a reason for the delay or an expected publication date, stating only that "The Company will make further announcements as appropriate." The release described Mr Miller as executive chairman in one place and non-executive chairman in another.

The situation mirrors events a year earlier. On 1 October 2025, the company announced a similar delay and suspension, and it published final results on 14 October 2025, followed the next day by a subscription announcement that included director dealing.

The last reported numbers

The most recent published financial statements are the half-year results to 30 September 2025, published on 30 December 2025. They showed a loss of £334,800 for the six months, compared with £409,626 a year earlier. Net Assets were £1.83 million, down from £2.33 million, while cash stood at just £32,713, against £50,823. Borrowings totalled £276,705, up from £230,023. The board said the company "continues to manage its limited Working Capital prudently". On these figures, the cash balance at the half-year date was well below the loss reported for the six-month period, which underlines the importance of external funding.

The chairman acknowledged that "the Company's working capital position remains constrained due to the absence of revenue-generating operations." The directors said they were reviewing a range of share and Debt funding options, and that the board "expects that 2026 may deliver further updates on progress with the regulatory approval pathway." No announcements were published between that report and the 1 October 2026 suspension.

Risks and uncertainties

The suspension removes the ability to trade the shares until accounts are published and trading is restored. The company has very limited cash, no revenue and modest borrowings, which suggests it is reliant on new funding to continue developing its products. The absence of a stated reason for the delay leaves open whether it reflects audit timing, funding or other matters. The regulatory pathway for its spinal devices also remains uncertain, and the gap of nine months without announcements limits visibility on progress.

Conclusion

TSP Advanced Technologies is suspended because its audited accounts for the year to 29 March 2026 were not ready by the deadline, repeating last year's pattern. Its last reported figures show a pre-revenue company with constrained working capital. Publication of the accounts, any funding news and clarity on its regulatory progress will determine when, and on what basis, trading can resume. Until then, shareholders have no market in which to buy or sell the shares.